Brachytherapy, also referred to as internal radiation therapy or curietherapy, is an oncological treatment designed to achieve precise local tumor control. By placing sealed radioactive materials—such as Iridium-192, Iodine-125, or Palladium-103—directly into or near cancerous cells, clinicians deliver concentrated radiation doses to the malignancy. The fundamental biological principle relies on the inverse-square law of physics: radiation intensity falls off rapidly as distance from the source increases. Consequently, critical nearby organs receive significantly lower radiation doses compared to conventional external beam radiotherapy, reducing overall toxicity while maximizing cancer cell destruction through double-stranded deoxyribonucleic acid (DNA) damage.

Brachytherapy begins with patient preparation and anesthesia administration. The clinical team positions specialized applicator needles, tubes, or tandem-and-ovoid devices into the target tissue using image guidance such as ultrasound, computed tomography, or magnetic resonance imaging. Once applicators are secured, imaging scans are acquired and transmitted to a computerized treatment planning system. Radiation oncologists and medical physicists map the target volume and surrounding healthy organs, optimizing the precise dwell positions and times for the radioactive source. In high-dose-rate brachytherapy, the applicator connects to a remote afterloader machine containing a single high-activity radioactive source, usually Iridium-192. The machine steps the source through the applicator tubes according to the treatment plan, delivering radiation over several minutes. Once completed, the source automatically retracts into the shielded machine, the applicators are removed, and the patient enters the recovery area.

Clinical evidence demonstrates several key advantages of brachytherapy in cancer care:

• Superior Target Dose Escalation: Delivers higher biologically effective radiation doses directly to the tumor compared to external techniques, enhancing local control rates (NCCN Guidelines 2024).
• Normal Tissue Preservation: Rapid radiation dose fall-off minimizes radiation exposure to adjacent organs at risk, such as the rectum, bladder, small intestine, or healthy skin.
• Shorter Overall Treatment Duration: HDR protocols often complete treatment in 1 to 5 fractions over several days, compared to 5 to 8 weeks required for conventional external beam radiotherapy.
• Organ and Function Preservation: Preserves critical anatomical structures and physiological functions in organ-sparing management of head and neck, gynecological, and prostate cancers.
• Lower Systemic Toxicity: Highly localized field reduces systemic fatigue, skin reactions, and widespread tissue inflammation.

Recovery from brachytherapy depends on the treatment site, application technique, and dose protocol:

• Immediate Phase (0–48 Hours): Patients undergoing HDR treatment generally recover from anesthesia within hours and are discharged same-day. Localized soreness, light bleeding, or minor urinary frequency may occur. For LDR temporary implants, patients remain hospitalized until applicator removal.
• Short-Term Phase (1–4 Weeks): Acute inflammation subsides. Patients with pelvic brachytherapy may experience temporary dysuria, urinary urgency, or mild bowel irritation, managed with oral medications. Normal daily activities are typically resumed within several days.
• Long-Term Phase (1–12 Months): Tissues heal and radiation response stabilizes. Routine follow-up visits include physical examination, blood tests (such as prostate-specific antigen for prostate cancer), and imaging to evaluate therapeutic response and screen for late tissue effects.

Brachytherapy is indicated for a wide array of solid tumors across primary, recurrent, and palliative clinical settings:

• Prostate Cancer: Used as monotherapy for low- and favorable intermediate-risk disease, or as a dose-escalation boost with external beam radiation for high-risk presentations (American Brachytherapy Society 2020 guidelines).
• Cervical Cancer: Essential component of definitive therapy for locally advanced cervical carcinoma, significantly improving overall survival (ESTRO GEC-ESTRO guidelines 2021).
• Endometrial Cancer: Administered as post-operative vaginal cuff brachytherapy to prevent vaginal vault recurrence in intermediate-risk disease.
• Breast Cancer: Utilized as accelerated partial breast irradiation (APBI) in early-stage, node-negative disease following breast-conserving surgery.
• Soft Tissue Sarcomas: Placed within the surgical bed to reduce local recurrence risks after resection.
• Head and Neck Malignancies: Applied for lip, oral cavity, and nasopharyngeal cancers to preserve organ function and anatomy.
• Ocular Melanoma: Delivered via custom episcleral plaques to eradicate intraocular tumors while preserving visual acuity.

Preparation for brachytherapy includes a comprehensive medical evaluation, physical examination, and diagnostic imaging to determine exact tumor measurements. Patients may undergo blood testing, including complete blood counts and coagulation profiles. Medications that affect blood clotting, such as aspirin, warfarin, or direct oral anticoagulants, are typically held several days prior to applicator placement under medical direction. For pelvic procedures, bowel preparation using oral laxatives or enemas is performed the day before to clear the rectum and improve visualization. Fasting instructions are provided based on the planned anesthesia technique. Patients receive clear guidance regarding hygiene, medication adjustments, and post-procedure transportation arrangements.

Complications from brachytherapy are divided into acute and late events. Acute side effects occur during or shortly after treatment and include localized swelling, mild bleeding, discomfort at the applicator site, transient urinary frequency, dysuria, and rectal irritation. These acute symptoms usually resolve within a few weeks with conservative medical management. Late complications develop months to years after treatment due to tissue fibrosis or vascular changes. These rare but serious side effects may include tissue necrosis, stricture formation in the urethra or vagina, radiation cystitis, chronic radiation proctitis, or fistula formation between adjacent pelvic organs. Advanced image-guided treatment planning drastically minimizes these late toxicities by enforcing strict radiation limits on healthy surrounding structures.

The clinical journey for brachytherapy consists of five structured stages:

• Pre-Treatment Workup: Cross-sectional imaging via computed tomography (CT) or magnetic resonance imaging (MRI) establishes anatomical boundaries and tumor volume. Patients undergo cardiovascular, laboratory, and anesthesia evaluations.
• Applicator Placement: Under appropriate anesthesia (general, spinal, or local with sedation), specialized delivery devices such as needles, catheters, or hollow applicators are positioned inside or near the target volume.
• Treatment Planning and Dosimetry: Real-time intraoperative imaging verifies applicator positioning. Radiation oncologists and medical physicists calculate optimal dwell times and radiation distribution using computerized software.
• Radiation Delivery: For high-dose-rate (HDR) procedures, a computerized remote afterloading machine connects to the applicators, stepping the radioactive source through programmed points for several minutes before retracting it. For low-dose-rate (LDR) procedures, radioactive seeds are either permanently implanted or temporarily inserted for 24–72 hours.
• Applicator Removal and Follow-Up: Temporary applicators are removed immediately post-treatment. Patients undergo recovery observation, acute toxicity screening, and structured long-term oncological surveillance.